Singapore, Feb. 18 -- Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected by Drake Rayden Foundation to apply the AAV Curator(R) Platform to manufacture clinical grade AAV for the Treatment of Nonketotic Hyperglycinemia (NKH), a rare, inherited metabolic genetic disorder caused by a mutation in the GLDC gene.

NKH is a debilitating disease that causes a disruption of the glycine cleavage system (GCS), leading to the inability of the body to break down the amino acid glycine. Glycine builds up to toxic levels, particularly in the brain, which leads to severe neurological problems including seizures, lethargy, poor muscle tone, breathing...